Collagen drinks are everywhere, and so is the doubt about whether swallowing collagen does anything for your face. A new randomized trial in the Journal of Cosmetic Dermatology tested a twist: wrap the collagen tripeptides in liposomes. Of the two collagen formulations, only the liposomal one produced a statistically significant reduction in wrinkle area versus placebo at Week 8.
That is a striking result. It also comes with caveats you should know before you buy anything.
The Head-to-Head: What Researchers Actually Tested
The team ran a randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov: NCT06771388) in 75 healthy adults aged 25-65. Participants were assigned to one of three groups:
- Placebo
- A nonliposomal formulation containing collagen tripeptides
- A liposomal formulation containing collagen tripeptides
Both active products were given at 50 mL per day for 8 weeks. Nobody was relying on self-reported glow. Researchers used standardized instruments to measure dermal collagen density, skin hydration, elasticity, wrinkle area, skin luminance and tone evenness. Measurements were taken at baseline and at Weeks 2, 4 and 8.
The Headline Finding: Wrinkles
Both collagen groups improved on several measures. Wrinkle area was where they separated.
Only the liposomal group showed a significant reduction in wrinkle area at Week 8 relative to placebo (p < 0.05). The nonliposomal group did not reach significance on that measure.
One nuance matters here. The abstract frames this as liposomal versus placebo. It does not say the liposomal product beat the regular one on wrinkles in a direct comparison. The wrinkle result is a difference in which group cleared the significance bar against placebo, not proof of a head-to-head win.
Where Liposomal Won Head-to-Head: Elasticity
The one direct advantage the authors report is for skin elasticity. At Week 8, the liposomal formulation showed a statistically significant advantage over the nonliposomal one (p < 0.05).
The researchers also report that the liposomal product showed an earlier onset and greater magnitude of improvement across multiple parameters. The abstract gives no specific effect sizes, so treat that as a directional signal rather than a number to quote.
What Both Collagen Formulations Did
Compared with placebo, both collagen tripeptide groups showed significant improvements (p < 0.05) in:
- Dermal collagen density
- Skin hydration
- Skin elasticity
Both groups also showed significant increases in skin luminance and tone evenness. In other words, the regular collagen product was not a dud. Liposomal delivery seems to have added speed, magnitude and the wrinkle signal on top.
Why Liposomes?
Liposomes are tiny lipid-based vesicles used to encapsulate ingredients. The working idea is that encapsulation improves delivery or bioavailability. The abstract does not report blood levels or tissue uptake, so the trial shows that outcomes differed, not why. The mechanism is an assumption here, not something this study demonstrated.
Practical Takeaways
Dose and duration: The studied regimen was 50 mL per day for 8 weeks. The abstract does not specify time of day or whether the product was taken with food, so there is no evidence-based timing advice from this paper.
Who it might suit: The participants were healthy adults aged 25-65. The results say nothing about people with skin disease, older adults, or anyone on medications that affect skin. Whether men and women responded differently is not reported in the abstract.
What to expect: Changes were measured with instruments. Differences a device detects are not always differences you or a friend would notice in the mirror. The abstract does not report any visual or subjective assessment.
Don't assume it's just collagen: The products are described as "collagen tripeptide-containing formulations." That phrasing implies the liquids may have contained other ingredients, and the abstract does not list them. A different product with plain collagen tripeptides may not behave the same way.
The Fine Print
This is where a critical reader should slow down.
- Industry link: Several authors are affiliated with TCI Co. Ltd., and the article carries a TCI copyright line. The paper's conflict-of-interest statement declares none, but the industry association is worth weighing when you read the glowing conclusion.
- Short duration: Eight weeks tells us nothing about long-term maintenance or whether benefits persist after stopping.
- Small trial: With 75 participants split across three arms, the groups are small. Subtle differences between the two active formulations are harder to pin down at this size.
- Single study: It needs independent replication, ideally with identical formulations differing only in delivery.
- Wrinkle comparison: As noted, the wrinkle finding is relative to placebo, so it is not a decisive liposomal-versus-regular verdict.
Bottom Line
This randomized, double-blind trial adds a credible data point to the case for oral collagen peptides and suggests that liposomal delivery may give an extra edge. The strongest claims are that both formulations beat placebo on collagen density, hydration and elasticity, that liposomal beat the nonliposomal on elasticity at Week 8, and that only the liposomal group showed a significant wrinkle-area reduction versus placebo. Promising, yes. Definitive, no. Wait for independent replication before treating liposomal collagen as a proven upgrade.